Grifols has received approval from the FDA for a new higher potency formulation of its rabies immune globulin (human) (HyperRAB) for rabies post-exposure prophylaxis.
The product is administered immediately after a person is exposed to the rabies virus. The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options, offering a greater concentration of anti–rabies virus antibodies within each milliliter of volume, and for patients, the potential